Latest Content

Catch up on recent regulatory decisions by the FDA in oncology, including actions in lung, hematologic, genitourinary, and gastrointestinal cancers.

With evolving standards for handling hazardous drugs, nurses must comply with safety and handling guidelines.

Emily Coiro, MSN, AGACNP-BC, BMTCN; and Julie Zgola, BSN, RN, who work in stem cell transplantation, were matched with patients in need of a transplant.

Through the highs and lows of working in oncology nursing, being present with colleagues and patients alike is a gift.

Kristin Daly, MSN, ANP-BC, AOCNP, shares advice for preparing patients for possible adverse effects outside of clinic hours.

The FDA has approved durvalumab plus FLOT for the treatment of patients with resectable gastric or gastroesophageal junction adenocarcinoma.

Emily Shelby, MSN, FNP-C, emphasized that referrals to other specialties is key to managing heavily pretreated patients with metastatic colorectal cancer.

Pembrolizumab plus paclitaxel with or without bevacizumab boosted survival in patients with platinum-resistant, recurrent ovarian cancer.

The FDA has approved intravenous or subcutaneous pembrolizumab combined with enfortumab vedotin-ejfv in the neoadjuvant and adjuvant MIBC settings.

Elizabeth Hubert, APRN, explains how to treat patients receiving luspatercept for low-risk myelodysplastic syndromes.

The addition of atezolizumab to BCG did not yield improved EFS compared with BCG alone in patients with high-risk non–muscle-invasive bladder cancer.

The FDA has converted its accelerated approval to a standard one for tarlatamab in extensive-stage small cell lung cancer.